Pular para o conteúdo principal
Ranking Invest

FSTX - F-star Therapeutics, Inc.

Segmento: HealthcareF-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Análise Ranking Invest

Valuation estimado
-$ 67.51 Mi
Último Balanço Atualizado: 3T2022

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 56.94 Mi

Dívida Líquida

-$ 22.89 Mi

L4T

-$ 44.99 Mi

MM4T

-522.63%

Indicadores Básicos

ROE

-79.02%

Índices de Previsibilidade

Receita Líquida

G1.17

Lucro

C0.32

Margem

D1.06

Índices de Tendência

Receita Líquida

D2.25

Lucro

F-6.04

Margem

F-5.70

Índices de Endividamento

DIV/PAT

-0.40

DIV/L4T

0.51

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.